Vascular response following implantation of the third-generation drug-eluting resorbable coronary magnesium scaffold: an intravascular imaging analysis of the BIOMAG-I first-in-human study
This imaging substudy revealed that, at 12-month follow-up, virtually all struts of the DREAMS 3G scaffold became invisible, without evident malapposition. The vascular healing response to DREAMS 3G implantation also appeared favourable up to 12 months, which is indicated by advanced strut degradation and spontaneous regressing PNT between 6 and 12 months.
Authors
- Michael Haude (ORCID: https://orcid.org/0000-0002-1364-840X)
- Juan F. Iglesias (ORCID: https://orcid.org/0000-0002-1669-6036)
- Marcus Wiemer (ORCID: https://orcid.org/0000-0003-4781-8064)
- Johan Bennett (ORCID: https://orcid.org/0000-0002-8301-4517)
- Masaru Seguchi (ORCID: https://orcid.org/0000-0002-5875-613X)
- Jan Torzewski (ORCID: https://orcid.org/0000-0003-4959-7293)
- Adrian Włodarczak (ORCID: https://orcid.org/0000-0003-3104-7728)
- Göran Olivecrona (ORCID: https://orcid.org/0000-0002-8935-4328)
- Bert Ferdinande (ORCID: https://orcid.org/0000-0003-4492-2675)
- Ralph Töelg
- Javier Escaned (ORCID: https://orcid.org/0000-0003-4932-0112)
- Héctor M. García‐García (ORCID: https://orcid.org/0000-0001-5100-0471)
- Paul Vermeersch (ORCID: https://orcid.org/0000-0002-3290-3453)
- Erion Xhepa (ORCID: https://orcid.org/0000-0002-0728-2819)
- Alp Aytekin (ORCID: https://orcid.org/0000-0001-9450-1591)
- Gábor G. Tóth (ORCID: https://orcid.org/0000-0002-0283-9091)
- René J. van der Schaaf
- Michael Joner
- Ron Waksman
Institutions
- Medical University of Graz (AT)
- Kempten University of Applied Sciences (DE)
- Christian-Albrechts-Universität zu Kiel (DE)
- OLVG (NL)
- University Hospital of Geneva (CH)
- Skåne University Hospital (SE)
- Lukaskrankenhaus (DE)
- Deutsches Herzzentrum München (DE)
- Ziekenhuis Oost-Limburg (BE)
- Segeberger Kliniken (DE)
- Asklepios (DE)
- Johannes Wesling Klinikum Minden (DE)
- KU Leuven (BE)
Publication Details
- Journal
- EuroIntervention
- Published
- 2024-09-01
- DOI
- https://doi.org/10.4244/eij-d-24-00055
- Citations
- 3
- Primary Topic
- Coronary Interventions and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 1.72
Funders
- AstraZeneca
- Edwards Lifesciences
- Boston Scientific Corporation
- ReCor Medical
- InfraRedx